Integrase strand transfer inhibitors in the management of HIV-positive individuals (Q38192022)

30 August 2017

1 reference

title

Integrase strand transfer inhibitors in the management of HIV-positive individuals (English)

1 reference

30 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579911%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

4

Mark A Wainberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579911%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Veronica Zanichelli

3

1 reference

ORCID Public Data File 2021

Peter K Quashie

series ordinal

2

object named as

Peter K Quashie

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579911%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

English

0 references

publication date

3 March 2014

1 reference

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579911%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579911%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579911%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

123-129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24579911%20AND%20SRC:MED&resulttype=core&format=json

Management of HIV infection in treatment-naive patients: a review of the most current recommendations

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Integrase and integration: biochemical activities of HIV-1 integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

The structural biology of HIV-1: mechanistic and therapeutic insights

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Dolutegravir for treatment of HIV: SPRING forwards?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Elvitegravir: a once-daily inhibitor of HIV-1 integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Dolutegravir for the treatment of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Raltegravir and etravirine are active against HIV type 1 group O.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 r

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Raltegravir with optimized background therapy for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Pharmacology of HIV integrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

HIV-1 integrase inhibitor resistance and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Resistance to HIV integrase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

HIV Drug Resistance and the Advent of Integrase Inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2014.883169